Immunovia - Discover and develop tools for early diagnosis of cancers

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

Immunovia and
IMMray™ technology
(10 min)

Financial reports

April 2020

Immunovia AB published the company’s Interim Report Jan-March 2020 on Tuesday, April 28, 2020, at 16.00 p.m. CET.

Financial reports


20 August, 2020
Interim report Jan-June 2020
Place: Immunovia website
21 August, 2020
FOKUS Patient
Place: Stockholm, Sweden
3 September, 2020
Pareto Securities’ 11th Annual Health Care Conference
Place: Stockholm, Sweden
All events

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports